U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07752069) titled 'Phase I Clinical Study Evaluating the Relative Bioavailability of Different Formulations of HRS-5346 in Healthy Participants' on Aug. 04.
Brief Summary: This study is a single center, randomized, open label crossover trial planned to include 50 healthy participants to evaluate the relative bioavailability of HRS-5346 new and old formulations in healthy participants. The experimental process includes three stages: screening period, baseline period, and administration observation period.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Lipoprotein Disorder
Intervention:
DRUG: HRS-5346
Dose A, Dose B
DRUG: HRS-...